Compare Stocks: IBIO, ARTV, SRZN, and CLLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$11.30 -2.0%	$9.70	$2.22 ▼ $14.53	$563.70M	2.16	377,904 shs	253,266 shs
CLLS Cellectis	$3.18 +8.2%	$2.93	$2.35 ▼ $5.48	$295M	2.91	17,862 shs	10,053 shs
IBIO iBio	$1.40 -4.8%	$1.54	$0.66 ▼ $3.82	$73.03M	1.3	624,471 shs	507,493 shs
SRZN Surrozen	$23.73 -1.9%	$22.89	$10.11 ▼ $35.00	$280.86M	0.52	270,575 shs	432,920 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-1.99%	-2.42%	+20.86%	+15.54%	+323.22%
CLLS Cellectis	+8.16%	+18.22%	+10.42%	-18.88%	+13.98%
IBIO iBio	-4.76%	+0.72%	-2.78%	-4.76%	+139,999,900.00%
SRZN Surrozen	-1.90%	+9.66%	+8.46%	-15.70%	+135.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$11.30 -2.0%	$9.70	$2.22 ▼ $14.53	$563.70M	2.16	377,904 shs	253,266 shs
CLLS Cellectis	$3.18 +8.2%	$2.93	$2.35 ▼ $5.48	$295M	2.91	17,862 shs	10,053 shs
IBIO iBio	$1.40 -4.8%	$1.54	$0.66 ▼ $3.82	$73.03M	1.3	624,471 shs	507,493 shs
SRZN Surrozen	$23.73 -1.9%	$22.89	$10.11 ▼ $35.00	$280.86M	0.52	270,575 shs	432,920 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-1.99%	-2.42%	+20.86%	+15.54%	+323.22%
CLLS Cellectis	+8.16%	+18.22%	+10.42%	-18.88%	+13.98%
IBIO iBio	-4.76%	+0.72%	-2.78%	-4.76%	+139,999,900.00%
SRZN Surrozen	-1.90%	+9.66%	+8.46%	-15.70%	+135.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	2.83	Moderate Buy	$39.00	245.13% Upside
CLLS Cellectis	2.83	Moderate Buy	$7.00	120.13% Upside
IBIO iBio	3.13	Buy	$5.00	257.14% Upside
SRZN Surrozen	2.67	Moderate Buy	$42.00	76.99% Upside

Current Analyst Ratings Breakdown

Latest IBIO, ARTV, SRZN, and CLLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
7/28/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/21/2026	ARTV Artiva Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CLLS Cellectis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SRZN Surrozen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/29/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/24/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/8/2026	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$41.00
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	2,209.83	N/A	N/A	$4.48 per share	2.52
CLLS Cellectis	$79.59M	4.01	N/A	N/A	$0.41 per share	7.76
IBIO iBio	$400K	173.88	N/A	N/A	$0.90 per share	1.56
SRZN Surrozen	$3.48M	79.17	N/A	N/A	($19.21) per share	-1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$83.86M	-$3.30	N/A	N/A	N/A	N/A	-83.31%	-70.63%	N/A
CLLS Cellectis	-$67.59M	-$0.65	N/A	N/A	N/A	-102.34%	-94.19%	-21.34%	N/A
IBIO iBio	-$18.38M	-$0.58	N/A	N/A	N/A	N/A	-53.86%	-46.48%	9/4/2026 (Estimated)
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-96.11%	N/A

Latest IBIO, ARTV, SRZN, and CLLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q4 2026	IBIO iBio	-$0.07	N/A	N/A	N/A	$0.08 million	N/A
8/6/2026	Q2 2026	ARTV Artiva Biotherapeutics	-$0.6251	-$0.63	-$0.0049	-$0.63	N/A	N/A
8/6/2026	H1 2026	CLLS Cellectis	-$0.2630	-$0.22	+$0.0430	-$0.22	$11.05 million	$6.90 million
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	8.16	8.16
CLLS Cellectis	1.61	1.37	1.37
IBIO iBio	N/A	11.88	11.88
SRZN Surrozen	N/A	11.91	11.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
CLLS Cellectis	63.90%
IBIO iBio	7.90%
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	1.80%
CLLS Cellectis	16.41%
IBIO iBio	2.75%
SRZN Surrozen	31.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	48.89 million	24.27 million	N/A
CLLS Cellectis	290	100.34 million	83.87 million	Optionable
IBIO iBio	100	49.68 million	48.31 million	N/A
SRZN Surrozen	80	11.61 million	7.93 million	Not Optionable

IBIO, ARTV, SRZN, and CLLS Headlines

Recent News About These Companies

What is HC Wainwright's Forecast for Surrozen Q3 Earnings?

August 14 at 1:28 AM | americanbankingnews.com

What is HC Wainwright's Estimate for Surrozen Q3 Earnings?

August 12 at 6:11 AM | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Surrozen (NASDAQ:SRZN)

August 12 at 1:48 AM | americanbankingnews.com

HC Wainwright Reiterates "Buy" Rating for Surrozen (NASDAQ:SRZN)

August 10, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Issues Quarterly Earnings Results, Beats Expectations By $0.88 EPS

August 6, 2026 | marketbeat.com

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | globenewswire.com

Perceptive Advisors LLC Makes New $6.68 Million Investment in Surrozen, Inc. $SRZN

August 2, 2026 | marketbeat.com

Surrozen, Inc. (NASDAQ:SRZN) Given Consensus Rating of "Moderate Buy" by Brokerages

July 30, 2026 | marketbeat.com

Surrozen, Inc. $SRZN Position Reduced by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Upgraded by Zacks Research to Hold Rating

July 30, 2026 | marketbeat.com

Surrozen (NASDAQ:SRZN) Major Shareholder Sells $6,906,250.00 in Stock

July 29, 2026 | insidertrades.com

Surrozen Inc

July 28, 2026 | edition.cnn.com

Insider Selling: Surrozen (NASDAQ:SRZN) Major Shareholder Sells 325,000 Shares of Stock

July 28, 2026 | marketbeat.com

Surrozen highlights Wnt retina pipeline, SZN-8141 IND timeline at HC Wainwright

July 22, 2026 | msn.com

Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright

July 22, 2026 | marketbeat.com

Surrozen to Present at Upcoming Healthcare Investor Conference

July 15, 2026 | globenewswire.com

Surrozen, Inc. (NASDAQ:SRZN) Sees Large Growth in Short Interest

July 15, 2026 | marketbeat.com

Surrozen (SRZN) Stock Forecast & Price Target

June 4, 2026 | investing.com

We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate

May 17, 2026 | finance.yahoo.com

Surrozen (SRZN) price target increased by 10.11% to 43.52

May 14, 2026 | msn.com

Surrozen Shareholders Support Board, Auditor and Pay Policies

May 14, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, ARTV, SRZN, and CLLS Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$11.30 -0.23 (-1.99%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$11.30 +0.00 (+0.04%)

As of 06:02 AM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Cellectis NASDAQ:CLLS

$3.18 +0.24 (+8.16%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$3.18 0.00 (-0.03%)

As of 04:10 AM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

iBio NASDAQ:IBIO

$1.40 -0.07 (-4.76%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$1.41 +0.01 (+1.00%)

As of 04:11 AM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Surrozen NASDAQ:SRZN

$23.73 -0.46 (-1.90%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$23.82 +0.09 (+0.40%)

As of 04:00 AM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, ARTV, SRZN, and CLLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, ARTV, SRZN, and CLLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, ARTV, SRZN, and CLLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, ARTV, SRZN, and CLLS Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Cellectis NASDAQ:CLLS

iBio NASDAQ:IBIO

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, ARTV, SRZN, and CLLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, ARTV, SRZN, and CLLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, ARTV, SRZN, and CLLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, ARTV, SRZN, and CLLS Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Cellectis NASDAQ:CLLS

iBio NASDAQ:IBIO

Surrozen NASDAQ:SRZN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools